New hope for teens with severe hay fever: xolair shows promise
NCT ID NCT04648930
First seen Mar 25, 2026 · Last updated May 18, 2026 · Updated 9 times
Summary
This study looked at the safety and effectiveness of the drug Xolair in teenagers aged 12 to 17 with severe seasonal allergies (hay fever) that didn't get better with standard treatments. Researchers tracked side effects and how well the drug worked in 50 participants. The goal was to see if Xolair could help control symptoms when other options failed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.